Navigation Links
OncoPlex Diagnostics Announces the Addition of the Androgen Receptor Protein to Their Quantitative Breast Cancer Proteomic Panel
Date:8/8/2014

ROCKVILLE, Md., Aug. 8, 2014 /PRNewswire/ -- OncoPlex Diagnostics has developed a quantitative androgen receptor (AR) assay to add to their Breast Cancer Proteomic Panel.  The OncoPlex Diagnostics Breast Panel simultaneously measures multiple clinically-relevant tumor proteins using mass spectrometry to better inform the oncologist on therapy selection. The Breast Cancer Proteomic Panel with the inclusion of AR was featured in a presentation at the 13th Annual International Future of Breast Cancer Meeting in Huntington Beach, CA on July 19 by Dr. April Speed, Breast Surgical Oncologist, Atlanta, GA. Dr. Speed highlighted AR as a biomarker included in the multi-protein quantitation panel with EGFR, HER2, HER3, IGF1R, MET, PD-L1, and ROS1. In addition, chemotherapy guidance markers FR-alpha, hENT1, RRM1, SPARC, TOPO1, and TOPO2A are included from just two tissue sections. 

Approximately 75% of all breast cancer patients express AR, including 10-20% of all triple negative breast cancer (TNBC) patients.  Historically, women with TNBC have had limited options for treatment based on guideline-driven algorithms. AR positive TNBC patients represent a unique breast cancer subtype where new treatment options may be available.  Androgen receptor inhibitors that are FDA approved for prostate cancer are currently in clinical trials for breast cancer.  "Recent data are emerging to support androgen receptor as a drug target in breast cancer today," stated Dr. Speed, referring to data from Dr. Joyce O'Shaughnessy's group presented at the 2013 San Antonio Breast Cancer Symposium.

OncoPlex Diagnostics Protein Panels
OncoPlex Diagnostics targeted therapy panels provide actionable results for specific solid tumor indications from only two formalin-fixed, paraffin-embedded (FFPE) tissue slides.  The OncoPlex Diagnostics patented Liquid Tissue® process solubilizes FFPE tissue from micro-dissected tumor samples for precise protein quantitation by mass spectrometry analysis. This patented process includes the introduction of a control peptide for each target of interest, ensuring extremely high specificity and no false positives.

About OncoPlex Diagnostics
OncoPlex Diagnostics is the only CAP-accredited, CLIA-certified laboratory to solubilize tumor cell proteins from FFPE tissue and measure the unique peptides in the sample with absolute quantitation.  Genomic mutation analysis by Next Generation Sequencing can also be derived from the same sample. This innovative approach provides more than 20 actionable proteomic results and 50 gene mutation analysis from two tissue sections preserving precious biopsy material.


'/>"/>
SOURCE OncoPlex Diagnostics
Copyright©2014 PR Newswire.
All rights reserved

Related biology news :

1. 2012 Forecast for US Molecular Diagnostics Market Now Available From Global Information Inc.
2. Portable diagnostics designed to be shaken, not stirred
3. Ultrasensitive biosensor promising for medical diagnostics
4. Creating a future of personalized medicine: U-M forms joint venture for DNA diagnostics
5. New Market Forecasts Available for Critical Global Biotechnology Testing and Screening Markets: Molecular Diagnostics, Hematology, Clinical Chemistry and Nucleic Acid Testing
6. NIH-funded genetic sequencing tool speeds drug discovery, disease diagnostics
7. Shared Medical Resources, LLC files suit against Histologics, LLC, Womens Health Laboratories and Avero Diagnostics for Willful Patent Infringement
8. Modern Mobility Aids, Inc. Announces a Revised Agreement for the Acquisition of Lumigene
9. ChromaDex® Announces Financial Results for the Year Ended 2011
10. Improved Authentication and Confidentiality Protection. ICAP Patent Brokerage Announces for Auction Important Patents in Data Encryption and Document Security
11. FirstMark Announces New Hire Jay Houtman as Southeast Regional Sales Manager
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/10/2019)... ... 2019 , ... When Dr. James L. Sherley, M.D., Ph.D., founder and director ... chapter to the new book Perinatal Stem Cells: Research and Therapy, he knew immediately ... debilitating secret of stem cell medicine. For more than a half-century, stem cell ...
(Date:1/8/2019)... and RALEIGH, N.C. (PRWEB) , ... January 07, ... ... micro acoustic and micro mechanical technologies and solutions for hearing instruments and specialty ... today announced BiometRIC, the first ever hearing aid receiver in canal with an ...
(Date:1/4/2019)... Texas (PRWEB) , ... January 02, 2019 , ... ... This release is particularly noteworthy, as the life science tools and service supplier ... it is offering a catalog. The catalog features not just part numbers like ...
Breaking Biology News(10 mins):
(Date:1/24/2019)... ... January 23, 2019 , ... Through ... awarded microbiome research support in study design, planning, sample collection, and analysis to ... St. Augustine Campus in Trinidad led by Dr. Elaine Monica Davis, MBBS, MPhil, ...
(Date:1/20/2019)... ... January 17, 2019 , ... Consumers are ... exclusive purview of physicians. That's changing as many services now exist for patients ... laboratory testing market totaled $208 million in 2018, according to Kalorama Information’s new ...
(Date:1/20/2019)... ... January 17, 2019 , ... TrakCel, the leading cell ... Quick Life Science Group (Quick Healthcare and QuickSTAT) today announce a partnership to ... cell and gene therapy industry to track products and manage the logistical processes ...
(Date:1/11/2019)... FEASTERVILLE, Pa. (PRWEB) , ... January 11, 2019 ... ... Collection Mixer (PN#: 302000) for the automated collection of donor blood. This ... blood collection experts. The unit incorporates the functionality needed for the busiest ...
Breaking Biology Technology: